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Available online 18 April 2019Objectives.We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian
cancer.
Methods.We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with
primary mEOC: FIGO stage II–IV or recurrence after stage I disease. Treatment arms were paclitaxel-carboplatin,
oxaliplatin-capecitabine, paclitaxel-carboplatin-bevacizumab, or oxaliplatin-capecitabine-bevacizumab. Chemo-
therapy was given 3-weekly for 6 cycles, and bevacizumab (3-weekly) was continued as maintenance (for
12 cycles). Endpoints included overall-survival (OS), progression-free survival (PFS), toxicity and quality of life
(QoL).
Results. The trial stopped after 50 patients were recruited due to slow accrual. Median follow-up was
59 months. OS hazard ratios (HR) for the two main comparisons were: 0.78 (p= 0.48) for Oxal-Cape vs. Pac-
Carbo (each with/without bevacizumab), and 1.04 (p = 0.92) for bevacizumab vs. no bevacizumab.Keywords:
Mucinous ovarian cancer
Chemotherapy
Rare tumor trial
Factorial designCancer Trials Centre, UK.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
542 M. Gore et al. / Gynecologic Oncology 153 (2019) 541–548Corresponding PFS HRs were: 0.84 and 0.80. Retrospective central pathology review revealed only 45% (18/40)
cases with available material had conﬁrmed primary mEOC. Among these, OS HR for Oxal-Cape vs. Pac-Carbo
was 0.36 (p= 0.14); PFS HR = 0.62 (p= 0.40). Grade 3–4 toxicity was seen in 61% Pac-Carbo, 61% Oxal-Cape,
54% Pac-Carbo-Bev, and 85% Oxal-Cape-Bev. QoL was similar between the four arms.
Conclusion.mEOC/GOG0241 represents an example of a randomized rare tumor trial. Logistical challenges led
to early termination, including difﬁculties in local histopathological diagnosis and accessing drugs outside their
labelled indication. There was misalignment between central funders who support clinical trials in rare cancers
and the deprioritisation of such work by those managing and funding research at a local level. Rare cancer trials
should include centralised pathology review before treatment.
Clinical trial registry number: ISRCTN83438782.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Epithelial ovarian cancer (EOC) consists of several subtypes, with
signiﬁcant differences in their clinical behavior and molecular charac-
teristics [1]. Mucinous epithelial ovarian cancer (mEOC) accounts for
~3–5% of ovarian cancers [2–4]. The proportion of EOCs considered to
be mucinous varies signiﬁcantly between countries (3–5% in Italy and
Japan, up to 30–39% in Singapore and South Korea); partly due to difﬁ-
culties in pathological diagnosis [5]. Survival rates for mEOC also differ
by country [6].
Most primary mEOCs are diagnosed early with good prognoses fol-
lowing surgery [7,8]. However, advanced stage or recurrent mEOCs re-
spond poorly to standard ovarian cancer chemotherapy. The relative
rarity of mEOC means they are included in treatment trials with com-
mon types of EOC, potentially masking signiﬁcant differences from
other subtypes. Within randomized trials of ovarian cancer, advanced
stage mEOC (stage III/IV disease or recurrence) treated with taxane/
platinum therapy has worse progression-free survival (PFS) and overall
survival (OS) than serous or other histologies [9–11]. Similar observa-
tions have been found in two case-control studies of patients treated
with ﬁrst-line platinum-based chemotherapy [12,13]; and in other ret-
rospective studies based on stage III/IV disease [14,15] or in patients
with recurrent stage I to IV disease [16,17].
Only one randomized trial (ICON3) has reported treatment compar-
isons speciﬁcally for mEOC patients, an exploratory subgroup analysis.
7% of 2074 patients had mEOC, with no difference in OS/PFS for
paclitaxel-carboplatin versus either carboplatin or cisplatin-
cyclophosphamide-doxorubicin [18]. The lack of evidence led us to es-
tablish the ﬁrst randomized trial designed speciﬁcally for this subtype.
This article also outlines direct experience of one of the ﬁrst rare
tumor trials conducted between the UK and US.
2. Methods
2.1. Study design
Weconducted amulti-center phase III factorial trial, with accrual be-
tweenMarch 2010 and August 2013 from 19 hospitals in the UK (called
‘mEOC’) and 12 hospitals in the US (GOG-0241). The twomain trial ob-
jectives were to show (i) that oxaliplatin/capecitabine are more effec-
tive than standard paclitaxel/carboplatin, and (ii) that outcomes could
be improved by adding bevacizumab to each of these two regimens.
2.2. Patients
Eligible patients had a reported histological diagnosis of primary
mEOC; aged ≥18 years; newly diagnosed FIGO stage II–IV, or recurrence
after stage I disease; no previous chemotherapy; ECOG performance
status 0–2; and with acceptable biochemistry. Patients were excluded
if they had brain metastases; synchronous endometrial cancer; malig-
nancies other than ovarian cancer within prior 5 years; and cardiovas-
cular disease precluding the use of bevacizumab. Patients wererandomly assigned by an electronic system at the Cancer Trials Centre
(UK) or GOG (US). Minimisation was used, with stratiﬁcation factors:
disease status (presence or absence of residual disease) and stage
(new/recurrent stages II–IV, or recurrent stage I), in each country.
2.3. Interventions
Patients were allocated 1:1:1:1 to the treatment arms, involving
ﬁrst-line chemotherapy (3-weekly cycles, for 6 cycles), with or without
concurrent bevacizumab, and those allocated to bevacizumab could
have this as single agent maintenance therapy for 12 further cycles
(Fig. S1):
• Carboplatin (AUC 5/6) and paclitaxel (175mg/m2), both intravenous,
day 1. [Pac-Carbo]
• Oxaliplatin (130 mg/m2 intravenous, day 1) and capecitabine
(850 mg/m2 orally twice daily, days 1–14) [Oxal-Cape]
• Carboplatin, paclitaxel, and bevacizumab (15 mg/kg intravenous
every 3 weeks), then bevacizumab maintenance (15 mg/kg on day
1, every 3 weeks). [Pac-Carbo-Bev]
• Oxaliplatin, capecitabine, and bevacizumab. [Oxal-Cape-Bev]
Carboplatin/paclitaxel was standard therapy for EOC at the time.We
investigated Oxal-Cape regimen because of high response rates seen in
colorectal cancer studies and that mEOCs exhibit ‘intestinal’ differentia-
tion [19–21]. Oxaliplatin has activity in advanced ovarian cancer [13,22],
and capecitabine was preferred over 5-ﬂurouracil because it is taken
orally andwas increasingly used. Bevacizumabwas another experimen-
tal therapy, to include an anti-VEGF therapy given promising ﬁndings in
ovarian cancer trials [23,24], and colorectal cancer.
2.4. Assessments
Clinical examination and biochemistry were performed at baseline,
6-weekly in the ﬁrst year, 3-monthly in the second year, and 6-
monthly during years 3–5. Abdominal and pelvic CT/MRI scans were
performed at baseline, the end of cycles 3 and 6, at weeks 30 and 42
post-randomization, 6-monthly in year 2, then annually in years 3–5.
Health-related quality of life (QoL) was assessed using the FACT-O TOI
and FACT/GOG NTX subscale. Imaging was also requested if patients
had any clinical symptoms of progression, or rising biomarkers (e.g.
CA125), according to local practice.
2.5. Histopathology
Tumor slides and the local pathology reports were reviewed cen-
trally by specialist gynecological pathologists (RZ, WGM, RG, NW), pri-
marily to distinguish primary ovarian from metastatic mucinous
carcinomas, using various established gross andmicroscopic pathologic
features [25,26].
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bilaterality, extraovarian involvement, small tumor size, involvement
of the capsular surface, a multinodular pattern with intervening areas
of normal ovarian parenchyma, inﬁltrative/destructive stromal inva-
sion, vascular invasion particularly at the ovarian hilum and signet
ring cells. While none of these features are pathognomonic formetasta-
tic mucinous carcinoma, their presence, especially in combination, are
strongly suggestive of this. Conversely, unilateral tumor, large tumor
size and an expansile pattern of invasion are suggestive of a primary
ovarian mucinous carcinoma. The presence of obvious benign and bor-
derline areas is also suggestive of an ovarian primary, although ovarian
metastatic mucinous carcinomas may exhibit a ‘maturation’ phenome-
non with mimicry of benign and borderline neoplasia. All the trial
cases exhibited extraovarian involvement at diagnosis or recurrence.
Immunohistochemistry may also assist in diagnosis, using markers
such as cytokeratins 7 and 20, CEA, CA19.9, CDX2, CA125, ER, p16,
SATB2 andPAX8, but these are often of limited value sincemost primary
ovarian mucinous carcinomas exhibit ‘intestinal’ differentiation with
expression of enteric markers.2.6. Statistical considerations
The primary endpoint was OS, with two main comparisons:
‘oxaliplatin/capecitabine’ versus ‘no oxaliplatin/capecitabine’, and
‘bevacizumab’ versus ‘no bevacizumab’. For each main comparison,
the target HR was 0.71. Assuming 5 years accrual then 18 months
follow-up, we required 330 patients (259 deaths) for each comparison
(80% power, two-sided 5% alpha, and 10% drop-outs).
OS was measured from randomization until death from any cause
(surviving patients were censored at the date last known to be alive).
PFS was measured from randomization until ﬁrst evidence of disease
progression or death whichever occurred ﬁrst; those without an event
were censored at the date they were last known to be alive. Tumor re-
sponse was assessed using RECIST. CA125 response was deﬁned as a
50% reduction from the pre-treatment CA125 value if maintained for
at least 28 days [27]. The same rule was applied to CEA and CA19-9 in
the absence recommended deﬁnitions of response for these markers.
Asymptomatic rising levels of CA125, CA19-9 or CEA alone required ra-
diological conﬁrmation of progression. Toxicity was graded by the Na-
tional Cancer Institute Common Terminology Criteria for Adverse
Events (v4.0).
Analyses were by intention-to-treat using Cox regression for the
main comparisons, and multivariable regression to explore interactions
between the therapies. The worst grade of adverse event for each pa-
tient and each toxicity was used. QoL was analysed by a repeated mea-
sures mixed model.Table 1
Baseline characteristics.
Paclitaxel +
carboplatin
n= 13
Oxaliplatin +
capecitabine
n = 13
Median age years (range) 55 (32–77) 56 (20–82)
Pre-treatment CA125, median (range),
IU/ml
46 (8–177) 31 (9–218)
Performance status
ECOG 0 8 10
ECOG 1 5 3
ECOG 2 0 0
FIGO stage
II 4 3
III 6 6
IV 1 1
Recurrent stage Ia 2 3
Conﬁrmed mEOCb 7 (43%) 1 (8%)
a No adjuvant chemotherapy given.
b After central pathology review.The Independent DataMonitoring Committee stopped the trial early
in 2013 because of poor accrual: only 50 patients out of the 330 target.
We collected long-term data on progression, deaths and clinic visit
dates (up to 21 February 2018) to observe more events.
3. Results
Baseline characteristics were balanced (34 UK and 16 US), Table 1.
Most patients (40 of 50) completed 6 cycles of combination chemother-
apy (Table S1). Among patients allocated to bevacizumab, 10 of 23 com-
pleted 12 cycles of maintenance therapy. Table S2 lists individual
patients known to have received post-trial treatment (the number
was similar between the four groups).
3.1. Tumor response
The complete/partial RECIST tumor response rate, among thosewho
were evaluable, was 27% (3/11) using Oxal-Cape, 40% (2/5) Oxal-Cape-
Bev, 43% (3/7) Pac-Carbo-Bev, and 22% (2/9) Pac-Carbo. Therewere two
complete responderswith Oxal-Cape, and one in each of the other three
groups. The number of patients with stable disease was: n = 5 Oxal-
Cape, n = 3 Oxal-Cape-Bev, n = 0 Pac-Carbo-Bev, and n = 1 Pac-
Carbo. The response rates were 31% (5/16) versus 31% (5/16) for any
Oxal-Cape versus any Pac-Carbo (p = 0.65); and 42% (5/12) versus
25% (5/20) for bevacizumab versus no bevacizumab (p-value = 0.27).
A similar number of patients had a CA125-response in each arm
(where assessable): 45% (5/11) Oxal-Cape, 50% (6/12) Oxal-Cape-Bev,
54% (6/11) Pac-Carbo-Bev, and 58% (7/12) Pac-Carbo. Among these 24
responders, the time from randomization until CA125-response was
63, 43, 43 and 34 days respectively. For the main comparisons, the
CA125-response rates were 48% (11/23) versus 56% (13/23) for any
Oxal-Cape versus any Pac-Carbo (p-value=0.38); and 52% (12/23) ver-
sus 52% (12/23) for bevacizumab versus no bevacizumab (p-value =
0.62). There was no difference in CA125 levels for either main compar-
ison when using patients' repeated measures over time (all p-values ≥
0.42).
CEA and CA19-9 levels were similar over time for patients. Using the
same deﬁnition of response as with CA-125 (acknowledging the limita-
tions of this), the number who had a CEA-response was: 1/8 Oxal-Cape,
1/9 Oxal-Cape-Bev, 2/10 Pac-Carbo-Bev, and 0/8 Pac-Carbo. The corre-
sponding numbers for CA19-9 response were: 1/9 Oxal-Cape, 4/9
Oxal-Cape-Bev, 2/9 Pac-Carbo-Bev, and 3/9 Pac-Carbo.
3.2. Progression-free and overall survival
After a median follow-up of 59 months, 34 patients had progressed
or died, and 31 had died (mainly disease progression).Paclitaxel + carboplatin +
bevacizumab
n= 11
Oxaliplatin + capecitabine +
bevacizumab
n= 13
47 (29–76) 51 (28–60)
23 (17–370) 21 (8–336)
5 11
5 2
1 0
4 4
5 8
1 1
1 0
3 (27%) 7 (54%)
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bevacizumab, clearly improved OS (Fig. 1) or PFS (Fig. S2); all p-values
≥ 0.70. OS was numerically superior for Oxal-Cape compared to Pac-
Carbo (median 33.9 versus 27.7 months, HR 0.77, p= 0.48). Similarly,
for PFS using bevacizumab (median 18.1 vs. 8.8 months; HR 0.87, p=
0.70).
Table 2 shows summary PFS and OS results. For all 50 patients, the
median PFS was 16.4 months, somewhat higher than in previous ran-
domized trials (7.6–11.4 months) [9–11]. The overall median OS
(27.8 months) was also higher than in those trials (14.6–21.6 months)
[9–11]. The 36-month rates for OS/PFS were also higher than expected
(~45–55%), though with wide 95%CIs. Potential differences in patients,
aswell as improvements inmanagement over time, should be acknowl-
edged when comparing our outcomes with previous ﬁndings.
We were particularly interested in the effect of adding bevacizumab
to Pac-Carbo (pre-speciﬁed analyses). The HRs were 1.12 (p = 0.82)
and 1.47 (p= 0.44) for PFS and OS respectively (Pac-Carbo-Bev versus
Pac-Carbo), i.e. no beneﬁt. Similarly, for adding bevacizumab to Oxal-
Cape, the HRs were 0.55 (p = 0.23) and 0.77 (p = 0.61) for PFS and
OS respectively (Oxal-Cape-Bev versus Oxal-Cape).
Fifteen of the 50 patients (30%) had at least 48 months without pro-
gression; 7 had stage III disease at diagnosis (Table 3). Notably, 9 pa-
tients were given Oxal-Cape (35%: 9/26) compared to 25% (6/24)
given Pac-Carbo (each with/without bevacizumab). Some of these 15
patients might have lacked macroscopic residual disease after surgery.
3.3. Adverse events and QoL
The percentage of patients who experienced any grade 3–4 toxicity
was: 61% (8/13) Oxal-Cape, 85% (11/13) Oxal-Cape-Bev, 54% (6/11)
Pac-Carbo-Bev, and 61% (8/13) Pac-Carbo (Tables 4 and S3). As ex-
pected, hypertension was more common among patients receivingFig. 1. Overall survival according to the two main protocol-deﬁned comparisons, ‘oxalipla
bevacizumab’, for all 50 patients (Panels A and B), and for patients with conﬁrmed mEOC af
between these two main experimental regimens (Panels A & B); interaction p= 0.37 for OS.bevacizumab. Alopecia was more common in those given paclitaxel:
83% (20/24) paclitaxel versus 23% (6/26) no paclitaxel.
QoL was similar across all treatment groups for physical and func-
tional well-being, and neurotoxicity (Table S4), with small differences
in total scores for both main comparisons (Table S5).
3.4. Central pathology review
Tumormaterial was available for retrospective central pathology re-
view in 40 of 50 cases. 18 (45%; 18/40) were conﬁrmed as having pri-
mary mEOC; the others were considered to represent metastatic
disease, usually from the upper/lower gastrointestinal tract or cervix.
There was no clear evidence that patients with conﬁrmed primary
mEOCs had different outcomes than those considered to have metasta-
tic neoplasms: HRs for primary mucinous versus metastatic tumors
were 1.03 (95%CI 0.48–2.19, p= 0.94) and 0.74 (95%CI 0.33–1.66, p=
0.46) for PFS and OS respectively, adjusted for the two main treatment
comparisons and FIGO stage.
Table 2 summarises PFS/OS for the 18 with conﬁrmed primary
mEOCs, and Figs. 1 and S2 show Kaplan-Meier curves. The number of
patients is too small to make any reliable conclusions. The PFS and OS
HRs for bevacizumab versus no bevacizumab were 0.76 (p = 0.62)
and 1.08 (p = 0.91) respectively. However, the PFS HR for Oxal-Cape
compared to Pac-Carbo (both with or without bevacizumab) was 0.62
(p = 0.40), while the OS curves were clearly separated in favor of
Oxal-Cape, with HR 0.36 (p= 0.14).
4. Discussion
ThemEOC/GOG-0241 trial is one of the ﬁrst US-UK collaborations to
establish rare tumor trials, and a precursor to the International Rare
Cancers Initiative [28]. We set up and conducted a randomizedtin + capecitabine versus no oxaliplatin + capecitabine’ and ‘bevacizumab versus no
ter central pathology review (Panels C and D). There was no evidence of an interaction
Table 2
Efﬁcacy summary.
Progression-free survival Overall survival
Median
months
At 12 months
% (95%CI)
At 36 months
% (95%CI)
Median
months
At 12 months
% (95%CI)
At 36 months
% (95%CI)
All patients randomized (n= 50)
All 4 groups together 16.4 52 (38–66) 42 (28–56) 27.8 68 (55–81) 47 (33–61)
Paclitaxel + carboplatina 36.1 54 (27–81) 54 (27–81) 37.6 61 (34–87) 54 (27–81)
Oxaliplatin + capecitabinea 7.4 31 (6–56) 31 (6–56) 27.8 69 (44–94) 46 (19–73)
Paclitaxel + carboplatin + bevacizumaba 15.4 54 (24–83) 36 (8–64) 27.7 64 (35–92) 33 (4–62)
Oxaliplatin + capecitabine + bevacizumaba 23.2 69 (44–94) 46 (19–73) 55.7 77 (54–99) 54 (27–81)
Primary comparisons
Oxaliplatin + capecitabine (±bevacizumab) 14.2 50 (31–69) 38 (19–57) 33.9 73 (56–90) 50 (31–69)
Paclitaxel + carboplatin (±bevacizumab) 16.4 54 (34–74) 46 (26–66) 27.7 63 (44–82) 45 (25–65)
Bevacizumabb 18.1 62 (43–81) 41 (21–61) 27.7 71 (53–89) 44 (24–64)
No bevacizumabc 8.8 42 (23–61) 42 (23–61) 32.7 65 (47–83) 50 (31–69)
Conﬁrmed mEOC (n= 18)
All 4 groups together 29.6 61 (38–83) 50 (27–73) 53.6 78 (59–97) 61 (38–83)
Primary comparisons
Oxaliplatin + capecitabine
(±bevacizumab)
38.6 75 (45–100) 50 (15–85) 68.8 100 75 (45–100)
Paclitaxel + carboplatin (±bevacizumab) 23.1 50 (19–81) 50 (19–81) 29.3 60 (30–90) 50 (19–81)
Bevacizumabb 33.7 70 (41–98) 50 (19–81) 53.6 80 (55–100) 60 (30–90)
No bevacizumabc 23.1 50 (15–85) 50 (15–85) 48.9 75 (45–100) 62 (28–95)
CI = Conﬁdence Intervals.
a Logrank test between all 4 arms: p= 0.72 PFS, p = 0.70 OS.
b Paclitaxel + carboplatin + bevacizumab and oxaliplatin + capecitabine + bevacizumab.
c Paclitaxel + carboplatin and oxaliplatin + capecitabine.
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We also showed the value of undertaking long-term follow-up. There
were two separate sponsors (US and UK) because of signiﬁcant issues
associatedwith having single or joint sponsorship for transatlantic stud-
ies, such as processing of contracts, costs, implications for Roche who
provided bevacizumab, and insurance.
No ﬁrm conclusions about best treatment options can be made.
However, we show slight evidence that oxaliplatin/capecitabine could
be investigated further. Our trial also provides estimates of OS/PFS
within a contemporary cohort of mEOC patients using high qualityTable 3
Individual patients without progression by 48 months from randomization (total number rand
Patient number Progression-free time, months Age FIGO stage Perform
Paclitaxel + carboplatin (n = 13)
1c 50 53 II
2 55 58 III
3 59 60 II
4 60 55 III
Oxaliplatin + capecitabine (n = 13)
5 51 57 III
6 52 61 II
7 63 54 Reca
8 85 26 III
Paclitaxel + carboplatin + bevacizumab (n = 11)
9 50 47 II
10e 60 55 II
Oxaliplatin + capecitabine + bevacizumab (n = 13)
11d 54 31 III
12 54 50 III
13 61 48 II
14 71 58 III
15 82 58 II
Chemo = chemotherapy.
Maint = maintenance with bevacizumab.
a Recurrence after stage I; no adjuvant chemotherapy given.
b After central pathology review.
c Died at 57 months.
d Died at 56 months.
e Had doxorubicin/cyclophosphamide 26months after ending trial treatment (all other patiendata, including pathologically conﬁrmed mEOC. The 3-year OS/PFS
rates seemed higher than in previous studies [10], with a notable num-
ber of long-term survivors without progression (Table 3).
Given the limited scientiﬁc impact of our trial, we focus our discus-
sion on the reasonswhy this study of a rare tumor failed. Few investiga-
tors have provided detailed information about their experiences of
conducting rare cancer trials. For example, in an international trial of
high-grade uterine leiomyosarcoma published in November 2018 in
the Journal of Clinical Oncology, only 38 patients were recruited out of
the target of 216, but there was a lack of reasons for the poor accrualomized patients in each group is shown).
ance status No. of chemo cycles No. of maint cycles Conﬁrmed mEOCb
0 3 No
0 6 Yes
1 6 Yes
0 6 No
0 6 No
0 6 Not known
0 6 Not known
0 6 No
0 6 0 No
1 6 12 No
0 6 12 Yes
0 6 12 Yes
0 6 1 Yes
1 6 4 No
1 6 12 Yes
ts in the table had no record of subsequent treatment after completing the trial treatment).
Table 4
Clinically relevant grade 3–4 adverse events. Number of patients for each type of event,
maximum grade per patient. (All adverse events set out in Supplemental Table S1).
Paclitaxel
+
carboplatin
n= 13
Oxaliplatin
+
capecitabine
n = 13
Paclitaxel +
carboplatin +
bevacizumab
n= 11
Oxaliplatin +
capecitabine +
bevacizumab
n = 13
Allergic reaction 1 1 . .
Bleeding . . . 2
Constipation . . . 1
Diarrhoea . 1 . 3
Dyspnoea . 1 . .
Fatigue . . 1 .
GI perforation . . . 1
Hand-foot
syndrome
. . . 2
Hypertension . 4 3 6
Nausea/vomiting . . . 2
GI, other . 1 . .
Pain 1 . 1 1
Peripheral
sensory
neuropathy
2 . . 1
Pneumothorax . 1 . .
Rash . 1 . .
Thromboembolic
event
. . 1 .
Vaginal bleeding . . . 1
Anaemia 1 . . 2
Low lymphocytes . . 1 .
Low neutrophils 5 1 1 .
Low platelets 2 . . .
Low white blood
cells
1 . 1 .
Hypomagnesemia . . 1 .
Abnormal
laboratory
values
. . 1 1
Any grade 3–4
eventa
8 (61%) 8 (61%) 6 (54%) 11 (85%)
a Each patient counted only once.
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can be learnt, for the beneﬁt of other researchers and funders.
Two trial-speciﬁc issues were encountered. Firstly, there were difﬁ-
culties with local pathology evaluation. Only 45% of patients were con-
sidered to have primary mEOCs on specialist central review, similar to
30% found by Zaino and colleagues [30]. Kommoss and colleagues
showed the impact of revised histopathological diagnostic approaches,
where one pathologist reviewed 23 mEOC cases in 2002, but only 9
were classiﬁed as primary mEOC when reviewed again in 2014 using
WHO criteria (blinded to the original diagnosis) [31]. Diagnostic criteria
are more standardized now with high inter-observer reproducibility
when classifying ovarian carcinomas. The second issue was the declin-
ing incidence of primary mEOC over time (from 10–12% to 3–5% cur-
rently), predominantly attributable to revised pathological assessment
and the realization that many advanced stage mEOCs represent metas-
tases from extraovarian sites [32].
Funders strongly encourage and provide signiﬁcant funding speciﬁ-
cally for uncommon/rare cancer trials, but our experience should in-
crease their awareness of some major practical difﬁculties. Firstly,
individual sites often consider the resources required for setting up
and conducting therapy trials, including contracts, to be disproportion-
ately high compared to the low number of patients they expect to re-
cruit. This is particularly problematic for non-commercial studies, who
usually do not provide initial set-up payments plus per patient costs
(unlike industry-sponsored trials). There were reports that those re-
sponsible for the local research budgets in the UK were unwilling to
support the trial for ﬁnancial/resource reasons, while prioritising trials
in commoner cancers.Secondly, several sites considered that oxaliplatin/capecitabine
were not a recommended treatment for mEOC, and so not prepared to
fund them locally. This was particularly disappointing because both
drugs are easily available, and with a low treatment cost so it would
have a tiny impact on an individual site's total anti-cancer therapy bud-
get, especially since most sites would recruit very few (1–3) patients
per year.WhenmEOC/GOG0241 started, the cost of oxaliplatin/capecit-
abine was ~£433 per cycle (£2598 for 6 cycles), or $692 per cycle
($4156 for 6 cycles). The issue of funding ‘experimental’ treatments
has a potential detrimental effect on precision medicine strategies and
trials usingmolecular targets for patient eligibility. Our experience sug-
gests that unless the targeted agent is funded/provided by industry,
local investigators could have difﬁculty persuading their funders to
pay for necessary trial drugs. In MEOC/GOG-0241, Roche provided
bevacizumab so there was no issue here, but the trial grants which
came from the NCI in the US and Cancer Research UK in the UK do not
fund treatments, hence wewere completely reliant on hospitals to pro-
vide oxaliplatin/capecitabine.
A third issuewas lack of support from investigators. In 2013, we sur-
veyed all active oncology trial sites in the US and UK, but only 57 out of
217 responded. We also surveyed 700 attendees at an annual Gyneco-
logic Oncology Group meeting, in which only 54 responded but about
half of the respondents believed the trial was still relevant. The low sur-
vey response rates suggested an overall lack of interest to proceed with
the trial locally.We believe that thiswas largely due to the site problems
raised above, because when the idea for the trial was ﬁrst initiated be-
fore 2008 there was strong international support for it, which is why
it proceeded to successful funding applications in both the US and UK.
Further evidence for these issues came from examining the number
of activated and recruiting centers. In the UK, 41 hospitals were acti-
vated of which 19 recruited; only 7 each recruited ≥2 patients, and the
rest each had one patient only. The US situation was worse, with only
12 out of 176 activated sites enrolling patients; only two each recruited
≥2 patients, and 10 each had only one patient. If every activated center
had recruited only two patients during the entire accrual period of
3.5 years, we would have 434 patients, including ~156 with conﬁrmed
primary mEOC. This would have been a major achievement and pro-
vided sufﬁcient data to help manage mEOC patients, particularly given
the factorial trial design.
Therapies are still typically based on organ of origin rather than on
molecular/genetic characteristics. Gene expression arrays show that
mucinous cancers are distinctly different from other subtypes [33].
About 50% of mucinous tumors have KRAS mutations and 20% HER2
ampliﬁcation, higher than with serous carcinomas, and both markers
generally seem associated with better survival and fewer recurrences
[31,34–36]. We assumed that mEOC tumors would respond in the
same favorable way to oxaliplatin-capecitabine as colorectal carcino-
mas, since both exhibit intestinal differentiation [19–21]. However,
while they share some common molecular alterations, they differ in
others: HER2 ampliﬁcation and KRAS mutations are more common in
mEOC while BRAF, APC and CTNNB1 mutations are less common [37].
Potential treatment approaches for mEOC might include immunother-
apy [38], radiotherapy [39], combination PI3K/mTOR and MEK
inihibitors [40], and oxaliplatin-dasatinib [41].
mEOC patients are disadvantaged because treatment regimens for
them do not have the same level of evidence as for other cancers. The
FifthOvarian Cancer Consensus Conference [42] concluded that recruiting
mEOC patients to trials remains important. In future studies, central pa-
thology review should be part of the eligibility criteria, possibly facilitated
by a review panel utilising digital technology, as successfully adopted in
the GOG281 trial. However, while other ovarian subtypes can be readily
diagnosed using a single histological section, the diagnosis of primary
mEOC is generally more problematic, requiring multiple sections to dis-
tinguish primary ovarian from metastatic neoplasms.
A key lesson learnt from mEOC/GOG-0241 is that international col-
laboration and well-intentioned support from research funders may
547M. Gore et al. / Gynecologic Oncology 153 (2019) 541–548be insufﬁcient for a successful trial in rare cancers. Two trials under the
International Rare Cancers Initiative have closed (NCT02051868 and
NCT01979523): one completed, and the other did not open in Europe
after all and stopped early. It would be important for these investigators
to report difﬁculties encountered. During mEOC/GOG-0241, problems
at sites included funding, prioritisation and administrative burden. Fu-
ture investigators attempting to establish rare tumor trials should ad-
dress these issues early and directly.
Conducting traditional randomized phase III studies are challenging
for rare tumors, and this is evenmore so with biomarker-directed ther-
apies within precision medicine research. We therefore need better
ways of evaluating experimental therapies for rare tumors such as
mEOC and also producing useful data to help guide treatments. This
may simply involve well conducted single-arm or small randomized
phase II trials, or adaptive designs [43]. An alternative is to take a ‘big
data’ approach and prospectively collect data in a systematic manner,
as well as using the information that already resides within the data-
bases of everymajor cancer centre, and couple it with central pathology
review and molecular analysis. Using real-world data could act as con-
trols for single arm trials of experimental therapies. Finally, we believe
that better progress can be made in treating rare tumors if there is a
closer connect between research funders and local decision-makers.
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